Otsuka Holdings Co., Ltd. (TSE: 4570) is a Japanese pharmaceutical company headquartered in Tokyo, Japan, founded in 2010 through the restructuring of Otsuka Pharmaceutical Co., Ltd. Otsuka is known for its innovative research in psychiatry, neurology, and oncology, with a strong focus on CNS disorders[1].
Otsuka has developed several important medications for neurological and psychiatric conditions and continues to invest in neurodegenerative disease research, particularly for Parkinson's disease and Alzheimer's disease. The company operates globally with 69 locations worldwide and generated approximately ¥1.74 trillion in revenue in 2022[2].
Otsuka Pharmaceutical was founded in 1964 by Toshihiko Otsuka. The company grew to become one of Japan's leading pharmaceutical companies with a focus on innovative medicines[2:1].
Key milestones:
Otsuka Holdings operates through multiple subsidiaries focused on different therapeutic areas:
Otsuka maintains a significant CNS portfolio with both approved products and development programs.
| Drug | Indication | Mechanism | Notes |
|---|---|---|---|
| Abilify (aripiprazole) | Schizophrenia, bipolar disorder | Dopamine D2 partial agonist | Top-selling antipsychotic |
| Rexulti (brexpiprazole) | Schizophrenia, major depressive disorder | Serotonin-dopamine activity modulator | Developed with Lundbeck |
| Lybalvi (olanzapine/samidorphan) | Schizophrenia, bipolar disorder | D2 antagonist + opioid antagonist | Opioid receptor modulation |
| Rejoyn | Major depressive disorder | Novel mechanism | Recently approved |
| Drug | Indication | Phase | Mechanism | Notes |
|---|---|---|---|---|
| S-474445 | Alzheimer's disease | Phase 1 | Amyloid aggregation inhibitor | Via Shionogi partnership |
| ATM-AkD | ALS | Preclinical | SOD1 targeting | Gene therapy approach |
| ASP-0742 | Parkinson's disease | Phase 1 | Novel target | In development |
| Drug | Indication | Phase | Notes |
|---|---|---|---|
| TS-142 | Treatment-resistant depression | Phase 2 | Novel mechanism |
| SEP-4199 | Bipolar depression | Phase 3 | Amino acid derivative |
Otsuka's neuroscience research focuses on:
Otsuka maintains key partnerships in the neuroscience space:
Otsuka is one of the leading CNS pharmaceutical companies globally:
Otsuka Holdings. 2024. ↩︎ ↩︎